Clinical Trial Update: EMMA-1 (Erbitux for Multiple Myeloma) [Phase 2]

View source ↗

Summary

EMMA-1, a Phase 2 trial of cetuximab (Erbitux) for multiple myeloma, has been terminated; no results are provided in the update.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Prof. Dr. Andreas Engert | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED